Study on pharmaceutical care model for drug-related problems in elderly patients based on comprehensive medication management review
- VernacularTitle:基于综合药物管理评价的老年患者药物相关问题的药学服务模式探索
- Author:
Hui GONG
1
,
2
;
Chen LI
3
;
Qing SHAN
1
;
Wei LIU
1
;
Hong CHEN
4
;
Chuan ZHAO
1
;
Hui ZOU
5
;
Zhuanqing HUANG
6
;
Mengli CHEN
1
Author Information
1. Dept. of Pharmacy，Medical Supplies Centre of PLA General Hospital，Beijing 100853，China
2. Graduate School of PLA General Hospital，Beijing 100853，China
3. Translational Medicine Center，Department of Medical Innovation and Research，PLA General Hospital，Beijing 100853，China
4. Cadre Diagnosis and Treatment Department，the Sixth Medical Center of PLA General Hospital，Beijing 100853，China
5. Outpatient Department，Jingzhong Medical District of PLA General Hospital，Beijing 100853，China
6. Dept. of Ophthalmology，the 944th Hospital of PLA，Gansu Jiuquan 735000，China
- Publication Type:Journal Article
- Keywords:
drug-related problems;
elderly patient;
comprehensive medication management review;
pharmaceutical care
- From:
China Pharmacy
2023;34(17):2162-2166
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the pharmaceutical care model for elderly patients with drug-related problems （DRPs） based on the comprehensive medication management review （CMMR）， and to observe the effect of pharmaceutical care under the model. METHODS The pharmaceutical care new model for elderly patients was established by concerning CMMR guidelines in Australia. In other words， clinical pharmacists receive medical care through referral by health practitioners and active consultation by patients or their caregivers. Visits were made by a combination of face-to-face and telephone interviews. Follow-up was carried out in the form of outpatient follow-up， telephone follow-up， appointment， and home guidance to know about the treatment of DRPs by healthcare practitioners or patients.Under this model， the occurrence status and classification of DRPs in elderly patients were studied through cross-sectional investigation. The effect of pharmaceutical care was evaluated from the aspects of hospitalization rate， adverse drug reaction （ADR） incidence，medication compliance， the number of medications， blood lipid level， etc.， through self-before-after comparison. RESULTS In this study， a patient-centered， evaluation-intervention-reevaluation closed-loop pharmaceutical care model was formed. Among 317 study subjects， the average number of DRPs was 1.03 （0-7） cases. Compared before and after the intervention， the number of drug types increased from 2.00（0.00，3.00） to 2.00（1.00，3.00）， but the level of low-density lipoprotein cholesterin in patients decreased from 3.48 （2.58， 4.29） mmol/L to 3.11 （2.29，3.81） mmol/L （P＜0.05）. There was no statistical significance in hospitalization rate， ADR incidence within or medication compliance. CONCLUSIONS CMMR-based pharmaceutical care model can effectively identify and manage the patients’ DRPs and reduce the level of blood lipid.
